Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · June 10, 2023

Impact of Brentuximab Vedotin Maintenance After ASCT on Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Haematologica

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Charles Gaulin MBBS

Haematologica
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes
Haematologica 2023 Apr 27;[EPub Ahead of Print], CB Wagner, K Boucher, A Nedved, IN Micallef, S Desai, H Hatic, G Goyal, E Zacholski, A Fegley, AM Sigmund, DA Bond, C Samuels, MK Kamdar, S Ba Aqeel, P Torka, K MacDougall, A Borogovac, S Rajeeve, S Sundaram, K Fedak, D Modi, E Travers, S Ayyappan, N Chilakamarri, EA Brem, DA Ermann, LA Fitzgerald, B Hu, DM Stephens, H Shah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated